[go: up one dir, main page]

RU2012150809A - CRYSTAL ANTIBODIES AGAINST HUMAN IL-12 - Google Patents

CRYSTAL ANTIBODIES AGAINST HUMAN IL-12 Download PDF

Info

Publication number
RU2012150809A
RU2012150809A RU2012150809/10A RU2012150809A RU2012150809A RU 2012150809 A RU2012150809 A RU 2012150809A RU 2012150809/10 A RU2012150809/10 A RU 2012150809/10A RU 2012150809 A RU2012150809 A RU 2012150809A RU 2012150809 A RU2012150809 A RU 2012150809A
Authority
RU
Russia
Prior art keywords
antibody
disease
crystallization
poly
crystallization method
Prior art date
Application number
RU2012150809/10A
Other languages
Russian (ru)
Inventor
Дэвид В. БОРХАНИ
Вольфганг ФРАУНХОФЕР
Ханс-Юрген КРАУЗЕ
Анетте КЕНИГСДОРФЕР
Герхард ВИНТЕР
Штефан ГОТТШАЛЬК
Original Assignee
Эббви Инк.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Инк., filed Critical Эббви Инк.,
Publication of RU2012150809A publication Critical patent/RU2012150809A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)

Abstract

1. Способ серийной кристаллизации для кристаллизации антитела против IL-12, указанный способ включает стадии:(a) получения водного раствора антитела в смеси по меньшей мере с одним полиалкиленгликолем в качестве кристаллизационного агента; и(b) инкубирования водной кристаллизационной смеси до образования кристаллов антитела.2. Способ кристаллизации по п.1, в котором рН водной кристаллизационной смеси находится в интервале примерно от рН 4 примерно до 6,5.3. Способ кристаллизации по п.1, в котором водная кристаллизационная смесь содержит буфер.4. Способ кристаллизации по п.3, в котором буфер содержит ацетатный буфер.5. Способ кристаллизации по п.4, в котором буфер содержит ацетат натрия.6. Способ кристаллизации по п.3, в котором концентрация буфера в водной кристаллизационной смеси составляет примерно до 0,5 М.7. Способ кристаллизации по п.1, в котором молекулярная масса полиалкиленгликоля находится в интервале примерно от 400 примерно до 10000.8. Способ кристаллизации по п.7, в котором полиалкиленгликоль представляет собой полиэтиленгликоль.9. Способ кристаллизации по п.1, в котором концентрация полиалкиленгликоля в кристаллизационной смеси находится в интервале примерно от 5 до 30% (масс./об.).10. Способ кристаллизации по п.9, в котором полиалкиленгликоль представляет собой полиэтиленгликоль.11. Способ кристаллизации по любому из предыдущих пунктов, в котором соблюдается по меньшей мере одно из следующих дополнительных условий кристаллизации:a) инкубирование проводят в течение примерно от 1 часа примерно до 250 дней;b) инкубирование проводят при температуре примерно от 4°С примерно до 37°С;c) концентрация антитела находится в интерва�1. A serial crystallization method for crystallizing an anti-IL-12 antibody, the method comprises the steps of: (a) preparing an aqueous solution of the antibody in a mixture with at least one polyalkylene glycol as a crystallization agent; and (b) incubating the aqueous crystallization mixture to form antibody crystals. 2. The crystallization method according to claim 1, in which the pH of the aqueous crystallization mixture is in the range from about pH 4 to about 6.5.3. The crystallization method according to claim 1, wherein the aqueous crystallization mixture contains a buffer. The crystallization method according to claim 3, wherein the buffer contains an acetate buffer. The crystallization method according to claim 4, wherein the buffer contains sodium acetate. The crystallization method according to claim 3, wherein the concentration of the buffer in the aqueous crystallization mixture is up to about 0.5 M. The crystallization method according to claim 1, in which the molecular weight of the polyalkylene glycol is in the range from about 400 to about 10000.8. The crystallization method according to claim 7, wherein the polyalkylene glycol is polyethylene glycol. The crystallization method according to claim 1, wherein the concentration of polyalkylene glycol in the crystallization mixture is in the range of about 5 to 30% (w / v). The crystallization method of claim 9, wherein the polyalkylene glycol is polyethylene glycol. The crystallization method according to any one of the preceding paragraphs, in which at least one of the following additional crystallization conditions is met: a) incubation is carried out for from about 1 hour to about 250 days; b) incubation is carried out at a temperature of from about 4 ° C to about 37 ° C; c) the concentration of the antibody is in the interval�

Claims (44)

1. Способ серийной кристаллизации для кристаллизации антитела против IL-12, указанный способ включает стадии:1. A serial crystallization method for crystallizing an anti-IL-12 antibody, said method comprising the steps of: (a) получения водного раствора антитела в смеси по меньшей мере с одним полиалкиленгликолем в качестве кристаллизационного агента; и(a) preparing an aqueous solution of the antibody in a mixture with at least one polyalkylene glycol as a crystallization agent; and (b) инкубирования водной кристаллизационной смеси до образования кристаллов антитела.(b) incubating the aqueous crystallization mixture to form crystals of the antibody. 2. Способ кристаллизации по п.1, в котором рН водной кристаллизационной смеси находится в интервале примерно от рН 4 примерно до 6,5.2. The crystallization method according to claim 1, in which the pH of the aqueous crystallization mixture is in the range from about pH 4 to about 6.5. 3. Способ кристаллизации по п.1, в котором водная кристаллизационная смесь содержит буфер.3. The crystallization method according to claim 1, in which the aqueous crystallization mixture contains a buffer. 4. Способ кристаллизации по п.3, в котором буфер содержит ацетатный буфер.4. The crystallization method according to claim 3, in which the buffer contains an acetate buffer. 5. Способ кристаллизации по п.4, в котором буфер содержит ацетат натрия.5. The crystallization method according to claim 4, in which the buffer contains sodium acetate. 6. Способ кристаллизации по п.3, в котором концентрация буфера в водной кристаллизационной смеси составляет примерно до 0,5 М.6. The crystallization method according to claim 3, in which the concentration of the buffer in the aqueous crystallization mixture is up to about 0.5 M. 7. Способ кристаллизации по п.1, в котором молекулярная масса полиалкиленгликоля находится в интервале примерно от 400 примерно до 10000.7. The crystallization method according to claim 1, in which the molecular weight of the polyalkylene glycol is in the range from about 400 to about 10,000. 8. Способ кристаллизации по п.7, в котором полиалкиленгликоль представляет собой полиэтиленгликоль.8. The crystallization method according to claim 7, in which the polyalkylene glycol is polyethylene glycol. 9. Способ кристаллизации по п.1, в котором концентрация полиалкиленгликоля в кристаллизационной смеси находится в интервале примерно от 5 до 30% (масс./об.).9. The crystallization method according to claim 1, wherein the concentration of polyalkylene glycol in the crystallization mixture is in the range of about 5 to 30% (w / v). 10. Способ кристаллизации по п.9, в котором полиалкиленгликоль представляет собой полиэтиленгликоль.10. The crystallization method according to claim 9, in which the polyalkylene glycol is a polyethylene glycol. 11. Способ кристаллизации по любому из предыдущих пунктов, в котором соблюдается по меньшей мере одно из следующих дополнительных условий кристаллизации:11. The crystallization method according to any one of the preceding paragraphs, in which at least one of the following additional crystallization conditions is met: a) инкубирование проводят в течение примерно от 1 часа примерно до 250 дней;a) incubation is carried out for about 1 hour to about 250 days; b) инкубирование проводят при температуре примерно от 4°С примерно до 37°С;b) incubation is carried out at a temperature of from about 4 ° C to about 37 ° C; c) концентрация антитела находится в интервале примерно от 0,5 примерно до 280 мг/мл.c) the antibody concentration is in the range of about 0.5 to about 280 mg / ml. 12. Способ кристаллизации по любому из п.1-10, дополнительно включающий стадию высушивания кристаллов.12. The crystallization method according to any one of claims 1 to 10, further comprising the step of drying the crystals. 13. Способ кристаллизации по любому из п.1-10, дополнительно включающий стадию обмена кристаллизационного маточного раствора искусственным маточным раствором.13. The crystallization method according to any one of claims 1 to 10, further comprising the step of exchanging the crystallization mother liquor with an artificial mother liquor. 14. Способ кристаллизации по любому из п.1-10, в котором объем партии находится в интервале примерно от 1 мл примерно до 20000 л.14. The crystallization method according to any one of claims 1 to 10, in which the batch volume is in the range from about 1 ml to about 20,000 liters. 15. Кристалл антитела против IL-12 человека.15. Crystal antibodies against human IL-12. 16. Кристалл антитела против IL-12 человека, полученный способом кристаллизации, охарактеризованным в п.1.16. A crystal of anti-human IL-12 antibody obtained by the crystallization method described in claim 1. 17. Кристалл по п.15 или 16, где кристалл имеет мечевидную морфологию.17. The crystal according to item 15 or 16, where the crystal has a xiphoid morphology. 18. Кристалл по п.15 или 16, где антитело представляет собой поликлональное антитело или моноклональное антитело.18. The crystal of claim 15 or 16, wherein the antibody is a polyclonal antibody or a monoclonal antibody. 19. Кристалл по п.18, в котором антитело выбрано из группы, состоящей из химерного антитела, гуманизированного антитела, негликозилированного антитела, антитела человека и мышиного антитела.19. The crystal of claim 18, wherein the antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, a non-glycosylated antibody, a human antibody, and a murine antibody. 20. Кристалл по п.15 или 16, в котором антитело представляет собой антитело IgG.20. The crystal of claim 15 or 16, wherein the antibody is an IgG antibody. 21. Кристалл по п.20, в котором антитело выбрано из группы, состоящей из антитела IgG1, IgG2, IgG3 и IgG4.21. The crystal according to claim 20, in which the antibody is selected from the group consisting of antibodies IgG1, IgG2, IgG3 and IgG4. 22. Кристалл по п.21, в котором антитело представляет собой антитело против IL-12 человека группы IgG1.22. The crystal according to item 21, in which the antibody is an anti-human IL-12 antibody of the IgG1 group. 23. Кристалл по п.22, где кристалл получают из выделенного антитела человека, которое диссоциирует от IL-12 человека с Kd 1·10-10 М или менее и константой скорости koff 1·10-3 с-1 или менее, обе величины определены с помощью поверхностного плазменного резонанса.23. The crystal according to item 22, where the crystal is obtained from an isolated human antibody that dissociates from human IL-12 with Kd 1 · 10 -10 M or less and a rate constant k off 1 · 10 -3 s -1 or less, both values are determined using surface plasma resonance. 24. Кристалл по п.23, где кристалл получен из выделенного антитела человека с вариабельной областью легкой цепи (LCVR), содержащей аминокислотную последовательность SEQ ID NO:2 и вариабельной областью тяжелой цепи (HCVR), содержащей аминокислотную последовательность SEQ ID NO:1.24. The crystal according to item 23, where the crystal is obtained from an isolated human antibody with a variable region of the light chain (LCVR) containing the amino acid sequence of SEQ ID NO: 2 and a variable region of the heavy chain (HCVR) containing the amino acid sequence of SEQ ID NO: 1. 25. Кристалл по п.23, где кристалл получают из антитела АВТ-874.25. The crystal according to item 23, where the crystal is obtained from antibodies ABT-874. 26. Фармацевтическая композиция, содержащая: (а) кристаллы антитела против IL-12 человека, охарактеризованные в п.15, и (b) по меньшей мере один фармацевтический эксципиент; где указанная композиция представлена в виде твердого, полутвердого или жидкого состава, каждый состав содержит антитело в кристаллической форме.26. A pharmaceutical composition comprising: (a) crystals of an anti-human IL-12 antibody, as described in claim 15, and (b) at least one pharmaceutical excipient; where the specified composition is presented in the form of a solid, semi-solid or liquid composition, each composition contains an antibody in crystalline form. 27. Фармацевтическая композиция, содержащая: (а) кристаллы антитела против IL-12 человека, охарактеризованные в п.15, и (b) по меньшей мере один фармацевтический эксципиент, в котором заключены или инкапсулированы кристаллы.27. A pharmaceutical composition comprising: (a) crystals of an anti-human IL-12 antibody described in Claim 15, and (b) at least one pharmaceutical excipient in which crystals are encapsulated or encapsulated. 28. Композиция по п.26 или 27, где указанная композиция имеет концентрацию антитела примерно выше 1 мг/мл.28. The composition according to p. 26 or 27, where the specified composition has an antibody concentration of approximately above 1 mg / ml 29. Композиция по п.28, где указанная композиция имеет концентрацию антитела примерно выше 200 мг/мл.29. The composition of claim 28, wherein said composition has an antibody concentration of greater than about 200 mg / ml. 30. Композиция по любому из п.26 и 27, где указанная композиция содержит по меньшей мере один носитель, выбранный из группы, состоящей из полимерного биоразлагаемого носителя, полимерного небиоразлагаемого носителя, масляного носителя и жидкого носителя.30. The composition according to any one of p and 27, where the specified composition contains at least one carrier selected from the group consisting of a polymeric biodegradable carrier, a polymeric non-biodegradable carrier, an oil carrier and a liquid carrier. 31. Композиция по п.30, где полимерный носитель представляет собой полимер, выбранный из одной или нескольких групп, состоящих из: поли(акриловой кислоты), поли(цианоактилатов), поли(аминокислот), поли(ангидридов), поли(депсипептида), поли(эфиров), поли(молочной кислоты), поли(молочной-со-гликолевой кислоты) или PLGA, поли (β-гидроксибутирата), поли(капролактона), поли(диоксанона); поли(этиленгликоля), поли(гидроксипропил)метакриламида, поли(органо)фосфазена, поли(ортоэфиров), поли(винилового спирта), поли(винилпирролидона), сополимеров малеинового ангидрида и алкилвинилового эфира, плюроновых полиолов, альбумина, альгината, целлюлозы и производных целлюлозы, коллагена, фибрина, желатина, гиалуроновой кислоты, олигосахаридов, гликаминогликанов, сульфатированных полисахаридов, их смесей и сополимеров.31. The composition according to p. 30, where the polymer carrier is a polymer selected from one or more groups consisting of: poly (acrylic acid), poly (cyanoactylates), poly (amino acids), poly (anhydrides), poly (depsipeptide) poly (esters), poly (lactic acid), poly (lactic-co-glycolic acid) or PLGA, poly (β-hydroxybutyrate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl) methacrylamide, poly (organo) phosphazene, poly (orthoesters), poly (vinyl alcohol), poly (vinyl pyrrolidone), copolymers of maleic anhydride and alkyl vinyl ether, pluronic polyols, albumin, alginate, cellulose, alginate, cellulose, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, mixtures thereof and copolymers. 32. Инъецируемая жидкая композиция, содержащая кристаллы антитела против IL-12 человека, охарактеризованные в п.15 или 16, концентрация антитела в которой находится в интервале примерно от 10 примерно до 400 мг/мл.32. An injectable liquid composition containing crystals of an anti-human IL-12 antibody, characterized in paragraph 15 or 16, the concentration of the antibody in which is in the range from about 10 to about 400 mg / ml 33. Кристаллическая суспензионная композиция, содержащая кристаллы антитела против IL-12 человека, охарактеризованные в п.15 или 16, концентрация антитела в которой примерно выше 100 мг/мл.33. A crystalline suspension composition containing crystals of an anti-human IL-12 antibody, characterized in paragraph 15 or 16, the concentration of the antibody in which is approximately above 100 mg / ml 34. Способ лечения млекопитающего, включающий стадию введения этому млекопитающему эффективного количества кристаллов антитела против IL-12 человека, охарактеризованных в п.15.34. A method of treating a mammal, comprising the step of administering to the mammal an effective amount of crystals of an anti-human IL-12 antibody, as described in claim 15. 35. Способ лечения млекопитающего, включающий стадию введения этому млекопитающему эффективного количества компзиции по п.26.35. A method of treating a mammal, comprising the step of administering to this mammal an effective amount of a composition according to claim 26. 36. Способ по п.34 или 35, в котором эту композицию вводят парентеральным путем, пероральным путем или путем инъекции.36. The method according to clause 34 or 35, in which this composition is administered parenterally, orally or by injection. 37. Способ лечения нарушения, связанного с IL-12, у пациента, указанный способ включает введение терапевтически эффективного количества кристаллов антитела по любому из пп.15, 16, 19 и 21-25.37. A method of treating a disorder associated with IL-12 in a patient, said method comprising administering a therapeutically effective amount of antibody crystals according to any one of claims 15, 16, 19 and 21-25. 38. Способ по п.37, в котором нарушение, связанное с IL-12, выбрано из группы, состоящей из ревматоидного артрита, остеоартрита, юношеского хронического артрита, артрита Лайма, псориатического артрита, реактивного артрита, спондилоартропатии, системной красной волчанки, болезни Крона, язвенного колита, воспалительного заболевания кишечника, инсулинзависимого сахарного диабета, тироидита, астмы, аллергических заболеваний, псориаза, дерматита, склеродермии, атопического дерматита, заболевания трансплантат против хозяина, отторжения органного трансплантата, острого или хронического иммунного заболевания, связанного с трансплантацией органов, саркоидоза, атеросклероза, диссеминированного внутрисосудистого свертывания, болезки Кавасаки, диффузного токсического зоба, нефротического синдрома, синдрома хронической усталости, гранулематоза Вегенера, болезни Шенлейн-Геноха, микроскопического васкулита почек, хронического активного гепатита, увеита, септического шока, синдрома токсического шока, септического синдрома, кахексии, инфекционных заболеваний, паразитарных заболеваний, синдрома приобретенного иммунодефицита, острого поперечного миелита, хореи Хантингтона, болезни Паркинсона, болезни Альцгеймера, инсульта, первичного биллиарного цирроза, гемолитической анемии, злокачественных опухолей, сердечной недостаточности, инфаркта миокарда, болезни Аддисона, спорадической полигландулярной недостаточности I типа и полигландулярной недостаточности II типа, синдрома Шмидта, (острого) респираторного дистресс синдрома взрослых, алопеции, очаговой алопеции, серонегативной артропатии, артропатии, болезни Рейтера, псориатической артропатии, артропатии при язвенном колите, энтеропатического синовита, хламидийной, иерсиниозной и сальмонелезной артропатии, спондилоартропатии, атероматозной болезни/артериосклероза, атопической аллергии, аутоиммунного буллезного заболевания, обыкновенной пузырчатки, листовидной пузырчатки, пузырчатки, болезни линейных IgA, аутоиммунной гемолитической анемии, гемолитической анемии с положительной пробой Кумбса, приобретенной пернициозной анемии, ювенильной пернициозной анемии, миалгического энцефалита/болезни госпиталя «Royal Free», хронического кандидоза кожи и слизистых, гигантоклеточного артериита, первичного склерозирующего гепатита, криптогенного аутоиммунного гепатита, синдрома приобретенного иммунодефицита, заболеваний, родственных приобретенному иммунодефициту, гепатита С, обычного изменчивого иммунодефицита (обычной вариабельной гипогаммаглобулинемии), дилятационной кардиомиопатии, женского бесплодия, угасания функции яичников, раннего угасания функции яичников, фиброзного заболевания легких, криптогенного фиброзирующего альвеолита, пост-воспалительного интерстициального заболевания легких, интерстициального пневмонита, интерстициального заболевания легких, связанного с заболеванием соединительной ткани, заболевания легких, связанного со смешанным заболеванием соединительной ткани, интерстициального заболевания легких связанного с системным склерозом, интерстициального заболевания легких, связанного с ревматоидным артритом, заболевания легких, связанного с системной красной волчанкой, заболевания легких, связанного с дерматомиозитом/полимиозитом, заболевания легких, связанного с болезнью Шегрена, заболевания легких, связанного с анкилозирующим спондилитом, диффузного заболевания легких, связанного с васкулитом, болезни легких, связанной с гемосидерозом, индуцированного лекарственными средствами интерстициального заболевания легких, лучевого фиброза, облитерирующего бронхиолита, хронической эозинофильной пневмонии, лимфоцитарного инфильтративного заболевания легких, пост-инфекционного интерстициального заболевания легких, подагрического артрита, аутоиммунного гепатита, аутоиммунного гепатита 1 типа (классический аутоиммунный или волчаночный гепатит), аутоиммунного гепатита 2 типа (анти-LKM антительный гепатит), гипогликемии, опосредованной аутоиммунными реациями, резистентности к инсулину типа В с акантокератодермией, гипопаратироидизма, острого иммунного заболевания, связанного с трансплантацией органов, хронического иммунного заболевания, связанного с трансплантацией органов, первичного склерозирующего холангита, идиопатической лейкопении, аутоиммунной нейтропении, NOS почечного заболевания, гломерулонефрита, микроскопического васкулита почек, болезни Лайма, хронической красной волчанки, идиопатического или NOS мужского бесплодия, аутоиммунитета к сперме, рассеянного склероза (всех подтипов), инсулин-зависимого сахарного диабета, симпатической офтальмии, вторичной легочной гипертензии вследствие болезни соединительной ткани, синдрома Гудпасчера, легочного проявления узелкового полиартериита, острой ревматической лихорадки, ревматоидного спондилита, болезни Стилла, системного склероза, синдрома Такаясу/артерита, аутоиммунной тромбоцитопении, идиопатической тромбоцитопении, аутоиммунного заболевания щитовидной железы, гипертиреоза, аутоиммунного гипотиреоза с зобом (болезнь Хашимото), атрофического аутоиммунного гипотиреоза, первичной миксодемы, белково-анафилактического увеита, первичного васкулита, витилиго, аллергии, аутоиммунного диабета, и аутоиммунного увеита.38. The method of claim 37, wherein the disorder associated with IL-12 is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn’s disease ulcerative colitis, inflammatory bowel disease, insulin-dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis, scleroderma, atopic dermatitis, graft versus host disease, organ rejection transplant, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki disease, diffuse toxic goiter, nephrotic syndrome, chronic fatigue syndrome, Wegener granulomatosis, active Shenoin-Genoch disease, hepatitis, microscopic vasculitis , uveitis, septic shock, toxic shock syndrome, septic syndrome, cachexia, infectious diseases, parasitic diseases acquired immunodeficiency syndrome, acute transverse myelitis, Huntington’s chorea, Parkinson’s disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignant tumors, heart failure, myocardial infarction, Addison’s disease, type I sporadic polyglandular insufficiency and type I polyglandular insufficiency , Schmidt syndrome, (acute) respiratory distress syndrome of adults, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reith disease RA, psoriatic arthropathy, arthropathy with ulcerative colitis, enteropathic synovitis, chlamydial, yersiniosis and salmonella arthropathy, spondyloarthropathy, atheromatous disease / arteriosclerosis, atopic allergy, autoimmune bullous disease, anemic fibrosis, pulmonary fibrosis, pulmonary fibrosis, pulmonary fibrosis, pulmonary fibroid, hemolytic anemia with positive Coombs test, acquired pernicious anemia, juvenile pernicious anemia, myalgic encephalitis / disease nor the Royal Free Hospital, chronic candidiasis of the skin and mucous membranes, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, acquired immunodeficiency syndrome, diseases related to acquired immunodeficiency, hepatitis C, common variable immunodeficiency, common variable hypogiemia, and varicose veins infertility, extinction of ovarian function, early extinction of ovarian function, fibrotic lung disease, cryptogenic fibrosing al veolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, interstitial lung disease associated with connective tissue disease, lung disease associated with mixed connective tissue disease, interstitial lung disease associated with systemic sclerosis, interstitial lung disease associated with rheumatoid arthritis, disease lung associated with systemic lupus erythematosus, lung disease associated with dermatomyositis / polymyositis, lung disease associated with Sjögren’s disease, lung disease associated with ankylosing spondylitis, diffuse lung disease associated with vasculitis, lung disease associated with hemosiderosis, drug-induced interstitial lung disease, radiation fibrosis, obliterating bronchiolitis, chronic eosinophilic pneumonia, lymphocyte lung disease, post-infectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, autoimmune type 1 hepatitis (classic autoimmune or lupus hepatitis), type 2 autoimmune hepatitis (anti-LKM antibody hepatitis), hypoglycemia mediated by autoimmune reactions, type B insulin resistance with acantokeratoderma, immune transport disease, hypoparathyroid disease an immune disease associated with organ transplantation, primary sclerosing cholangitis, idiopathic leukopenia, autoimmune neutropenia, NOS renal disease, glom rollonephritis, microscopic kidney vasculitis, Lyme disease, chronic lupus erythematosus, idiopathic or NOS male infertility, sperm autoimmunity, multiple sclerosis (all subtypes), insulin-dependent diabetes mellitus, sympathetic ophthalmia, secondary pulmonary hypertension, connective tissue disease, connective tissue disease, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu syndrome / artery, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goiter with autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary miksodemy, protein-anaphylactic uveitis, primary vasculitis, vitiligo, allergy, autoimmune diabetes, and autoimmune uveitis. 39. Применение кристаллов антитела против IL-12 человека, охарактеризованных в любом из пп.15, 16, 19 и 21-25 для получения фармацевтической композиции для лечения заболевания, связанного с IL-12, охарактеризованного в п.37.39. The use of crystals of antibodies against human IL-12, characterized in any one of paragraphs.15, 16, 19 and 21-25 to obtain a pharmaceutical composition for treating a disease associated with IL-12, described in clause 37. 40. Кристаллы антитела против IL-12 человека, охарактеризованные в любом из пп.15, 16, 19 и 21-25 для применения в медицине.40. Crystals of antibodies against human IL-12, characterized in any one of paragraphs.15, 16, 19 and 21-25 for use in medicine. 41. Способ кристаллизации по любому из пп.1-10, дополнительно включающий стадию увеличения выхода кристаллов путем добавления дополнительного количества полиалкиленгликоля.41. The crystallization method according to any one of claims 1 to 10, further comprising the step of increasing the yield of crystals by adding an additional amount of polyalkylene glycol. 42. Способ по п.41, в котором полиалкиленгликоль представляет собой полиэтиленгликоль.42. The method according to paragraph 41, in which the polyalkylene glycol is a polyethylene glycol. 43. Способ по п.41, в котором полиалкиленгликоль добавляют непрерывно.43. The method according to paragraph 41, in which the polyalkylene glycol is added continuously. 44. Способ кристаллизации по любому из пп.1-10, дополнительно включающий стадию затравки реакции с помощью кристаллов антител против IL-12 человека. 44. The crystallization method according to any one of claims 1 to 10, further comprising the stage of seeding the reaction using crystals of antibodies against human IL-12.
RU2012150809/10A 2007-03-29 2012-11-27 CRYSTAL ANTIBODIES AGAINST HUMAN IL-12 RU2012150809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92060807P 2007-03-29 2007-03-29
US60/920,608 2007-03-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009139922/10A Division RU2476442C2 (en) 2007-03-29 2008-03-27 Crystalline human il-12 antibodies

Publications (1)

Publication Number Publication Date
RU2012150809A true RU2012150809A (en) 2014-06-10

Family

ID=39808589

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009139922/10A RU2476442C2 (en) 2007-03-29 2008-03-27 Crystalline human il-12 antibodies
RU2012150809/10A RU2012150809A (en) 2007-03-29 2012-11-27 CRYSTAL ANTIBODIES AGAINST HUMAN IL-12

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2009139922/10A RU2476442C2 (en) 2007-03-29 2008-03-27 Crystalline human il-12 antibodies

Country Status (15)

Country Link
US (3) US8168760B2 (en)
EP (2) EP2142565A4 (en)
JP (2) JP2010522752A (en)
KR (1) KR20100014674A (en)
CN (1) CN101679507A (en)
AU (1) AU2008233173B2 (en)
BR (1) BRPI0809209A2 (en)
CA (1) CA2681752A1 (en)
IL (1) IL201184A0 (en)
MX (1) MX2009010361A (en)
NZ (2) NZ598881A (en)
RU (2) RU2476442C2 (en)
TW (2) TWI429657B (en)
WO (1) WO2008121301A1 (en)
ZA (2) ZA200906432B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258562B1 (en) 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU2002256971B2 (en) * 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
MX2007014440A (en) 2005-05-16 2008-02-11 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis.
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
JP2010507670A (en) 2006-10-27 2010-03-11 アボツト・バイオテクノロジー・リミテツド Crystalline anti-hTNFα antibody
SG177982A1 (en) * 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
MX2010001488A (en) * 2007-08-08 2010-03-01 Abbott Lab Compositions and methods for crystallizing antibodies.
CA2713342A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
BRPI0908715A2 (en) * 2008-03-18 2016-05-03 Abbott Lab Methods for psoriasis treatment
BRPI0921320A2 (en) * 2008-11-28 2018-05-22 Abbott Laboratories stable antibody compositions and methods for stabilizing them
TW201127400A (en) * 2009-09-14 2011-08-16 Abbott Lab Methods for treating psoriasis
EP2596123B1 (en) * 2010-07-22 2015-11-25 Shire Human Genetic Therapies, Inc. Crystal structure of human alpha-n-acetylglucosaminidase
WO2012135035A1 (en) * 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US8962888B2 (en) * 2012-12-03 2015-02-24 Physical Sciences, Inc. Forming spherical crystal habit
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AR103726A1 (en) * 2015-02-27 2017-05-31 Merck Sharp & Dohme HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112021008873A8 (en) 2018-11-07 2023-04-11 Merck Sharp & Dohme FORMULATION
WO2021152175A1 (en) * 2020-01-31 2021-08-05 Sanofi Pulmonary delivery of antibodies
JPWO2024195801A1 (en) * 2023-03-20 2024-09-26

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3631229A1 (en) * 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4897465A (en) * 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5811523A (en) * 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH0791318B2 (en) 1989-09-21 1995-10-04 三井東圧化学株式会社 Aqueous protein solution, method for increasing concentration of aqueous protein solution, and protein preparation
ATE168416T1 (en) * 1989-10-05 1998-08-15 Optein Inc CELL-FREE SYNTHESIS AND ISOLATION OF GENES AND POLYPEPTIDES
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
FR2708467B1 (en) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Stabilized immunoglobulin preparations and process for their preparation.
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
DE4344824C1 (en) * 1993-12-28 1995-08-31 Immuno Ag Highly concentrated immunoglobulin preparation and process for its preparation
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
WO1998016248A1 (en) 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PT936923E (en) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology BLENDING OF TNFALFA AND IL-12 IN THERAPY
CA2273194C (en) * 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP0998300A1 (en) 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO1998044948A2 (en) 1997-04-07 1998-10-15 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
US6162629A (en) * 1997-04-28 2000-12-19 Eli Lilly And Company Methods for processing activated protein C
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DK0911037T3 (en) * 1997-10-23 2002-12-02 Mitsubishi Pharma Corp At room temperature, shelf-life immunoglobulin preparation for intravenous injection
ATE274920T1 (en) 1997-10-31 2004-09-15 Wyeth Corp USE OF ANTI-IL-12 ANTIBODIES IN TRANSPLANT REJECTION
JP4481489B2 (en) 1998-01-23 2010-06-16 エフ．ホフマン−ラ ロシュ アーゲー Antibody against human IL-12
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
DE69927520T2 (en) * 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont USE OF IL-12 ANTIBODIES FOR THE TREATMENT OF PSORIASIS
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DK2168984T3 (en) * 1999-03-25 2012-12-10 Abbott Gmbh & Co Kg Human antibodies that bind human IL-12 and methods for its production
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
US7279146B2 (en) * 2003-04-17 2007-10-09 Fluidigm Corporation Crystal growth devices and systems, and methods for using same
DE10022092A1 (en) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilized protein preparation and process for its preparation
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATIONS FOR INJECTION
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
KR20030038690A (en) 2000-08-07 2003-05-16 인헤일 테라퓨틱 시스템즈 인크. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
DE60139944D1 (en) 2000-10-12 2009-10-29 Genentech Inc LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS
WO2002043750A2 (en) 2000-12-01 2002-06-06 Battelle Memorial Institute Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
US6693173B2 (en) * 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
AU2002256971B2 (en) * 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002098445A1 (en) * 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Protein preparation
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2002359495A1 (en) * 2001-11-30 2003-06-17 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
PL213311B1 (en) * 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Antibody-containing solution pharmaceuticals
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc Buffered formulations for concentrating antibodies and methods of use thereof
JP2006502116A (en) * 2002-07-12 2006-01-19 メダレックス， インク． Methods and compositions for preventing oxidative degradation of proteins
BR0312785A (en) 2002-07-19 2005-08-30 Abbott Biotech Ltd Treatment of Tnf-related disorders (alpha)
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
CA2504134C (en) * 2002-11-01 2012-03-06 Bayer Healthcare Llc Process for concentration of macromolecules
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7378110B2 (en) 2002-12-17 2008-05-27 Med Immune Vaccines, Inc. High pressure spray-dry of bioactive materials
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
EP1589996A4 (en) 2003-01-30 2009-01-21 Medimmune Inc Anti-integrin alpha beta 3 antibody formulat ions and uses thereof
PL1610820T5 (en) * 2003-04-04 2014-01-31 Genentech Inc High concentration antibody and protein formulations
WO2004102184A1 (en) 2003-05-09 2004-11-25 Arizeke Pharmaceuticals, Inc. Compositions and methods for concentrating polypeptides and proteins
AU2004220325B2 (en) * 2003-06-30 2011-05-12 Domantis Limited Polypeptides
HUE026793T2 (en) * 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
EP1688432B1 (en) * 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP1694317A4 (en) * 2003-12-19 2010-05-12 Protemix Corp Ltd ANTAGONIST COPPER COMPOUNDS
EP1713502A1 (en) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Highly concentrated liquid formulations of anti-egfr antibodies
KR100486028B1 (en) 2004-04-20 2005-05-03 주식회사 펩트론 Protein-containing lipid implant for sustained delivery and its preparation method
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US8008447B2 (en) 2004-07-23 2011-08-30 Genentech, Inc. Crystallization of antibody or fragment thereof
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20060194301A1 (en) * 2004-10-09 2006-08-31 Doctor Bhupendra P Large-scale production of human serum butyrylcholinesterase as a bioscavenger
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CN101120087A (en) 2004-12-21 2008-02-06 森托科尔公司 Anti-IL-12 antibodies, epitopes, compositions, methods and uses
CN101111264A (en) * 2005-01-28 2008-01-23 惠氏公司 Stabilized Liquid Peptide Formulations
US8349991B2 (en) * 2005-04-19 2013-01-08 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
ES2776657T3 (en) * 2005-06-14 2020-07-31 Amgen Inc Self-buffering protein formulations
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
CN103146708A (en) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40 binding proteins
WO2007003936A1 (en) 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
JP2009508470A (en) * 2005-07-21 2009-03-05 アボット・ラボラトリーズ Multiple gene expression including SORF constructs and polyprotein, proprotein and proteolytic methods
CA2634131C (en) * 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
JP5231810B2 (en) 2005-12-28 2013-07-10 中外製薬株式会社 Antibody-containing stabilized preparation
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US20070202051A1 (en) * 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
CN101495136A (en) 2006-02-15 2009-07-29 英克隆系统公司 Antibody formulations
DE102006030164A1 (en) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative powders
CN107243099A (en) * 2006-06-30 2017-10-13 艾伯维生物技术有限公司 Automated injection device
GB0615312D0 (en) 2006-08-02 2006-09-13 Univ Dundee Protein Solubilisation
SG175622A1 (en) 2006-10-13 2011-11-28 Centocor Ortho Biotech Inc Enhancement of hybridoma fusion efficiencies through cell synchronization
JP2010507670A (en) * 2006-10-27 2010-03-11 アボツト・バイオテクノロジー・リミテツド Crystalline anti-hTNFα antibody
AU2007329333A1 (en) * 2006-12-06 2008-06-12 Wyeth High protein concentration formulations containing mannitol
SG177982A1 (en) * 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
MX2009008769A (en) * 2007-02-16 2009-08-25 Wyeth Corp Protein formulations containing sorbitol.
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
MX2009011408A (en) * 2007-05-02 2009-11-05 Hoffmann La Roche Method for stabilizing a protein.
MX2010001488A (en) 2007-08-08 2010-03-01 Abbott Lab Compositions and methods for crystallizing antibodies.
KR20210049186A (en) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 Protein formulations and methods of making same
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
CA2713342A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
BRPI0908715A2 (en) * 2008-03-18 2016-05-03 Abbott Lab Methods for psoriasis treatment
BRPI0921320A2 (en) * 2008-11-28 2018-05-22 Abbott Laboratories stable antibody compositions and methods for stabilizing them
US8470308B2 (en) 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
NZ595885A (en) * 2009-04-29 2014-05-30 Abbvie Biotechnology Ltd Automatic injection device
CN102458469B (en) * 2009-05-04 2014-12-24 艾伯维生物技术有限公司 Stable high protein concentration formulations of human anti-TNF-α antibodies

Also Published As

Publication number Publication date
TW201350504A (en) 2013-12-16
EP2527364A1 (en) 2012-11-28
JP2014012674A (en) 2014-01-23
NZ580379A (en) 2012-10-26
US8404819B2 (en) 2013-03-26
CA2681752A1 (en) 2008-10-09
EP2142565A4 (en) 2010-03-31
US20140017256A1 (en) 2014-01-16
RU2476442C2 (en) 2013-02-27
US20120177704A1 (en) 2012-07-12
WO2008121301A1 (en) 2008-10-09
US8168760B2 (en) 2012-05-01
ZA201203820B (en) 2013-04-24
KR20100014674A (en) 2010-02-10
AU2008233173A1 (en) 2008-10-09
RU2009139922A (en) 2011-05-10
JP2010522752A (en) 2010-07-08
EP2142565A1 (en) 2010-01-13
TWI429657B (en) 2014-03-11
NZ598881A (en) 2013-11-29
ZA200906432B (en) 2015-08-26
MX2009010361A (en) 2009-10-16
AU2008233173B2 (en) 2013-09-19
BRPI0809209A2 (en) 2014-09-02
US20080292642A1 (en) 2008-11-27
US8940873B2 (en) 2015-01-27
CN101679507A (en) 2010-03-24
IL201184A0 (en) 2010-05-17
TW200906854A (en) 2009-02-16

Similar Documents

Publication Publication Date Title
RU2012150809A (en) CRYSTAL ANTIBODIES AGAINST HUMAN IL-12
RU2010107994A (en) COMPOSITIONS AND METHODS OF CRYSTALLIZING ANTIBODIES
JP2014012674A5 (en)
RU2486296C2 (en) CRYSTALLINE ANTIBODIES AGAINST hTNFα
US9512214B2 (en) Methods to control protein heterogeneity
US20090202557A1 (en) Compositions and methods for crystallizing antibody fragments
US20140271632A1 (en) Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP2011097946A5 (en)
JP7678761B2 (en) Sialylated glycoproteins
AU2022298245A1 (en) Novel polymer-coated crosslinked alginate gel fiber
CN112516301B (en) A liquid preparation of CD47 monoclonal antibody and its preparation method
AU2013203076A1 (en) Crystalline anti-human IL-12 antibodies
HK1179270A (en) Crystalline anti-human il-12 antibodies
RU2021115098A (en) CRYSTALS OF ANTIBODIES TO HUMAN PD-1 AND METHODS OF THEIR APPLICATION
AU2013202859A1 (en) Crystalline anti-hTNFalpha antibodies

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20151130